2015
New targets in breast cancer
Jhaveri A, Pusztai L. New targets in breast cancer. Memo - Magazine Of European Medical Oncology 2015, 8: 86-91. DOI: 10.1007/s12254-015-0197-5.Peer-Reviewed Original ResearchBreast cancerHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Novel clinical trial designsGrowth factor receptor 2Immune checkpoint modulatorsClinical trial designFactor receptor 2Akt/mammalian targetCyclin-dependent kinase 4/6Antibody-drug conjugatesPoly ADP-ribose polymeraseEndocrine therapyCheckpoint modulatorsADP-ribose polymeraseTherapeutic strategiesReceptor 2Trial designTherapeutic potentialMolecular abnormalitiesMammalian targetRapamycin (mTOR) pathwayNew drugsCancerNew targets
2013
Cancer heterogeneity: implications for targeted therapeutics
Fisher R, Pusztai L, Swanton C. Cancer heterogeneity: implications for targeted therapeutics. British Journal Of Cancer 2013, 108: 479-485. PMID: 23299535, PMCID: PMC3593543, DOI: 10.1038/bjc.2012.581.Peer-Reviewed Original ResearchConceptsIntra-tumoural heterogeneityIntra-tumor heterogeneityClinical trial designCancer therapeuticsDistinct genomic alterationsClinical outcomesMalignant tumorsCurrent evidenceTrial designSolid tumorsSubpopulation of cellsSame tumorTumorsTissue collectionGenomic alterationsTherapeuticsBiomarker discoveryWidespread implementationEvidence
2007
Limitations of pharmacogenomic predictor discovery in Phase II clinical trials
Pusztai L. Limitations of pharmacogenomic predictor discovery in Phase II clinical trials. Pharmacogenomics 2007, 8: 1443-1448. PMID: 17979517, DOI: 10.2217/14622416.8.10.1443.Peer-Reviewed Original Research